8-KRegulation FD

BOSTON SCIENTIFIC CORP 8-K Report, Regulation FD Disclosure (Jun 11, 2018)

Filed June 11, 2018For Securities:BSX

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report on June 11, 2018, addressing market speculation regarding a potential acquisition. The company acknowledges awareness of reports suggesting that Stryker Corporation has approached BSX about a possible takeover. However, in line with its standard policy, Boston Scientific has stated that it does not comment on market rumors or speculation. This disclosure is made under Regulation FD and is intended to inform investors and the market about the company's official stance on these unconfirmed reports.

Key Highlights

  • 1Boston Scientific acknowledges awareness of market speculation concerning a potential acquisition approach from Stryker Corporation.
  • 2The company officially states that it does not comment on market rumors or speculation.
  • 3The disclosure is made under Regulation FD to ensure fair and broad dissemination of information.
  • 4The filing does not confirm or deny the validity of the acquisition rumors.
  • 5Investors should note that this information is not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it does not carry the same liability as other filed information.

Frequently Asked Questions

The main purpose of this 8-K filing is to address and provide an official response to market speculation and rumors regarding a potential acquisition of Boston Scientific by Stryker Corporation, in compliance with Regulation FD.

No, Boston Scientific has not confirmed the rumors. The company stated that it does not comment on market rumors or speculation.

This filing does not provide a definitive answer. It only acknowledges awareness of the speculation and states the company's policy of not commenting on such rumors. Investors should not interpret this as confirmation or denial of any potential transaction.

This means that while the information is publicly disclosed, it is not subject to the same legal liabilities under Section 18 of the Securities Exchange Act of 1934 as other official filings. It is primarily a disclosure under Regulation FD to prevent selective disclosure.